Conmed Corp (CNMD) Stock Price & Analysis
Conmed Corp (CNMD) rose 3.42% to USD 42.68 as of July 25, 2026 at 07:45 UTC, according to Nexqual real-time market data.
CNMD last closed at USD 41.27; the session ranged USD 41.99–43.76 on volume of 340,158 shares. Market capitalization is $1.29B, with a 52-week range of USD 31.44–56.64 (NYQ). Source: Nexqual, July 25, 2026 at 07:45 UTC.
Key Statistics (as of July 25, 2026 at 07:45 UTC)
| Price | USD 42.68 |
|---|---|
| Change | ▲ 3.42% (up) |
| Previous Close | USD 41.27 |
| Open | USD 41.8 |
| Day Range | USD 41.99 – 43.76 |
| 52-Week Range | USD 31.44 – 56.64 |
| Volume | 340,158 shares |
| Market Cap | $1.29B |
| Exchange | NYQ |
Technical Analysis (CNMD)
Nexqual's technical model rates CNMD "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.32 (neutral) |
| vs SMA50 | Above (USD 36.54) |
| MACD | 2.08 (positive) |
Analyst Ratings (CNMD)
Wall Street analysts rate CNMD "Hold" based on 6 analysts, with a mean price target of USD 39 (range USD 36–40), per Nexqual as of July 25, 2026 at 07:45 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 39 |
| High Target | USD 40 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 0 / 6 / 1 |
Earnings (CNMD)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 1.11 |
| Revenue Estimate | $337.54M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.89 vs est 0.82 ▲ beat |
| 2025-12-31 | USD 1.43 vs est 1.32 ▲ beat |
| 2025-09-30 | USD 1.08 vs est 1.05 ▲ beat |
| 2025-06-30 | USD 1.15 vs est 1.12 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Financials & Fundamentals (CNMD)
| Total Revenue | $1.37B |
|---|---|
| Revenue Growth (YoY) | -1.30% |
| Gross Margin | +54.20% |
| Operating Margin | +10.61% |
| Profit Margin | +4.00% |
| ROE | +5.50% |
| Debt / Equity | 84.59 |
| Current Ratio | 2.29 |
| Total Cash | $35.03M |
| Total Debt | $860.87M |
| Free Cash Flow | $127.06M |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Financial Health Score (CNMD)
Nexqual rates Conmed Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:45 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 11% |
| Balance Sheet | Mixed — $35M cash vs $861M debt |
| Cash Flow | Solid — FCF $127M, 9% margin |
| Efficiency | Mixed — ROE 5%, ROA 3.8% |
Ownership (CNMD)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +116.80% |
| Shares Outstanding | 30.11M |
| Float | 29.81M |
| Short % of Float | +9.19% |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Leadership (CNMD)
Conmed Corp is led by Peter K. Shagory (age 56), Executive Vice President of Strategy & Corporate Development, per Nexqual as of July 25, 2026 at 07:45 UTC.
| Executive Vice President of Strategy & Corporate Development | Peter K. Shagory (age 56) |
|---|---|
| Vice President of Compliance | Keith Seaton |
| Executive Vice President of Human Resources | John David Ferrell (age 57) |
| President of ConMed Electrosurgery | David R. Murray (age 77) |
Major Backers & Investors (CNMD)
Notable institutional backers of Conmed Corp include Earnest Partners LLC, Fuller & Thaler Asset Management Inc., Bank of America Corporation, according to Nexqual as of July 25, 2026 at 07:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Earnest Partners LLC | 8.53% |
| Fuller & Thaler Asset Management Inc. | 5.45% |
| Bank of America Corporation | 4.66% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.55% |
| SEI Investments Co | 3.34% |
| Cooke & Bieler LP | 3.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.75% |
| Vanguard Group | 18.63% |
| Dimensional Fund Advisors | 4.63% |
| State Street | 4.6% |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
From Conmed Corp's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, our manufacturing processes and facilities, and those of third parties we contract with to provide regulated products and services, are subject to the FDA's Quality System Regulation ("QSR") and similar laws and regulations governing quality in other jurisdictions, and many of our products also are subject to industry-defined standards.
- We also pursue organic growth by focusing on our differentiated products.
- These products allow us to reach more surgeons and physicians and in turn also introduce other products in our portfolios. • Conduct Product Portfolio Review and Optimization.   We continuously review our product portfolio.
- The breadth of our product lines in our key product areas enables us to meet a wide range of customer requirements and preferences.  This has enhanced our ability to market our products to surgeons, hospitals, surgery centers, group purchasing organizations ("GPOs"), integrated delivery networks ("IDNs") and other customers, particularly as institutions seek to reduce costs and minimize the number of suppliers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OFIX | Orthofix Medical Inc. | USD 11.25 | ▲ 2.09% |
| ICUI | ICU Medical, Inc. | USD 157.44 | ▲ 0% |
| IART | Integra LifeSciences Holdings C | USD 19.79 | ▲ 5.15% |
| MMSI | Merit Medical Systems, Inc. | USD 74.32 | ▲ 1.66% |
| HAE | Haemonetics Corporation | USD 78.78 | ▲ 0.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:45 UTC. This page is informational and not investment advice.